Overview

Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities

Status:
Completed
Trial end date:
2014-01-31
Target enrollment:
Participant gender:
Summary
A study to determine the safety, tolerability, and efficacy of evolocumab (AMG 145) in patients with homozygous familial hypercholesterolemia (HoFH).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Evolocumab